Last reviewed · How we verify
NCT02154711
Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease
trial in Mitochondrial Disease in 40 participants. Completed in 30 June 2020.
30 June 2020
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 May 2014 |
| Primary completion | 30 June 2020 |
| Estimated completion | 30 June 2020 |
| Sites | 1 location across United States |
Conditions studied
- Mitochondrial Disease — all drugs for Mitochondrial Disease →
Sponsor
University of Pennsylvania
Who can join
Adults 18 to 65, any sex, with Mitochondrial Disease. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Creatine Recovery Time
Time frame: 15 minutes
Sponsor's own description
The purpose of the study is to use a new research imaging technique, a kind of magnetic resonance imaging (MRI), to measure important metabolic features of muscle, including mitochondrial function, in people with mitochondrial disease and in healthy individuals. (Mitochondria are tiny organelles that generate energy for the body.) It is hoped that this new strategy will help physicians to understand better the health problems of people with mitochondrial disease. Eventually, this could lead to better diagnostic and treatment approaches.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders.
DeBrosse C, Nanga RPR, Wilson N, D'Aquilla K, et al · · 2016 · cited 38× · PMID 27812541 · DOI 10.1172/jci.insight.88207 -
In vivo assessment of OXPHOS capacity using 3 T CrCEST MRI in Friedreich's ataxia.
Schur GM, Dunn J, Nguyen S, Dedio A, et al · · 2022 · cited 9× · PMID 34652504 · DOI 10.1007/s00415-021-10821-1
Verify or expand the search:
- PubMed search for NCT02154711
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mitochondrial Disease
Currently open trials in the same condition.
- NCT04419870 — Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity · recruiting
- NCT02000284 — Mitochondrial Dysfunction in Autism Spectrum Disorder · active not recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02154711 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 28 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02154711.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing